Second, while we controlled for major diabetes and obesity medications, we lacked granular information on the timing, dosage, and duration of GLP-1 RA use, and our cohort included several different GLP-1 RA formulations with varying pharmacologic properties. This evidence concerns the gene GLP1R and obesity disorder.